Agile Therapeutics (AGRX)
(Delayed Data from OTC)
$1.43 USD
-0.01 (-0.69%)
Updated Jul 9, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AGRX 1.43 -0.01(-0.69%)
Will AGRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AGRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AGRX
Supernus Pharmaceuticals (SUPN) Reports Q2 Loss, Misses Revenue Estimates
Are Medical Stocks Lagging Ardelyx (ARDX) This Year?
AGRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
TEVA Beats Q4 Earnings Estimates, Sales Miss & Stock Down
Is Ardelyx (ARDX) Stock Outpacing Its Medical Peers This Year?
Is Ardelyx (ARDX) Outperforming Other Medical Stocks This Year?
Other News for AGRX
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
Agile Therapeutics Merges with Insud Pharma Subsidiary
Agile Therapeutics to be acquired by Spain-based Insud for an enterprise value of ~$45M
Agile Therapeutics to be acquired by Insud Pharma for $1.52 per share in cash
Agile Therapeutics: Q1 Earnings Snapshot